Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isoquercetin Plus Standard of Care for COVID-19
NCT04536090Phase 2Withdrawn
- Sponsor
- Montreal Clinical Research Institute
- Start
- Jan 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of isoquercetin in coronavirus disease 2019 (COVID-19), sponsored by Montreal Clinical Research Institute. Planned start Jan 2022; status: withdrawn.
02
Drugs
isoquercetin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04536090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04536090.